Search Results for "vitamin D"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vitamin D. Results 11 to 20 of 27 total matches.

Tapinarof Cream (Vtama) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
. The topical retinoid tazarotene or a topical vitamin D analog such as calcipotriene or calcitriol have also ...
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be approved by the FDA.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):122-4 |  Show IntroductionHide Introduction

Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
such as tacrolimus or pimecrolimus, or the topical vitamin D analog calcipotriene is typically used.5 Phototherapy ...
The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab (Dupixent – Sanofi/Regeneron) for treatment of eosinophilic esophagitis (EoE) in patients ≥12 years old who weigh ≥40 kg and treatment of prurigo nodularis in adults. Dupilumab is the first drug to be approved in the US for each of these indications. It is also FDA-approved for treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):18-20   doi:10.58347/tml.2023.1669b |  Show IntroductionHide Introduction

Vutrisiran (Amvuttra) for Transthyretin Amyloid Cardiomyopathy

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
. Reductions in vitamin A levels are common with use of vutrisiran; vitamin A supplementation ...
The FDA has approved vutrisiran (Amvuttra – Alnylam), a subcutaneously injected small interfering RNA (siRNA), to reduce cardiovascular hospitalizations, urgent heart failure visits, and cardiovascular death in adults with wild-type or variant transthyretin amyloid cardiomyopathy (ATTR-CM). Vutrisiran is the first siRNA to be approved in the US for this indication; it was approved earlier for treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):102-4   doi:10.58347/tml.2025.1731b |  Show IntroductionHide Introduction

Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
[Colestid]) ▶ Generally not recommended ▶ May interfere with maternal absorption of vitamins ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2   doi:10.58347/tml.2025.1721b |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
; 10 mg/mL, 50 mg/5 mL oral soln Adult: 50-200 mg/d in 2 divided doses ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
(Eliquis), and edoxaban (Savaysa) are recommended over the oral vitamin K antagonist warfarin ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
Studies – In a randomized, double-blind trial comparing oral donepezil 10 mg/day, vitamin E 2000 IU/day ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):129-36 |  Show IntroductionHide Introduction

Comparison Table: Some Oral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
Effects and Drug Interactions Comments Cost2 Vitamin K Antagonist Warfarin3 – generic Jantoven (USL ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Med Lett Drugs Ther. 2022 Jul 25;64(1655):e122-4 |  Show IntroductionHide Introduction

Comparison Table: Some Lipid-Lowering Drugs (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
have been reported ▶ Treatment can result in very low LDL-C levels ( ...
View the Comparison Table: Some Lipid-Lowering Drugs
Med Lett Drugs Ther. 2022 Sep 19;64(1659):e152-6 |  Show IntroductionHide Introduction

Drugs for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025  (Issue 1719)
is caused by wet AMD.1 DRY AMD SUPPLEMENTS — Various oral vitamin and mineral supplements are promoted ...
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5   doi:10.58347/tml.2025.1719a |  Show IntroductionHide Introduction